Phase I study of docetaxel with concomitant thoracic radiation therapy

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
A M MauerE E Vokes

Abstract

The taxanes have demonstrated activity as radiation sensitizers in preclinical studies. This study was designed to determine the maximum-tolerated dose (MTD), optimal schedule, and toxicities of docetaxel in combination with concomitant standard chest radiotherapy. Twenty-nine patients with advanced non-small-cell lung or esophageal cancer enrolled in this phase I study to evaluate escalating docetaxel doses at three schedules. Docetaxel was administered as two 21-day cycles at doses of 40, 60, and 75 mg/m2 per cycle. Docetaxel administration schedules were as follows: schedule A, once every 3 weeks; schedule B, 2 of 3 weeks; or schedule C, weekly. Six weeks of concomitant standard chest radiotherapy in 1.8- to 2.0-Gy daily fractions was delivered to 60 Gy total. Dose-limiting esophagitis and neutropenia were encountered with schedules A and B at docetaxel doses of 60 mg/m2 per cycle. The docetaxel MTD for schedules A and B was 40 mg/m2 per cycle. Dose-limiting esophagitis was also observed with schedule C; however, there was no neutropenia. For schedule C, we identified the MTD as 60 mg/m2 per cycle (20 mg/m2/wk). Other toxicities encountered included thrombocytopenia, hypersensitivity reaction, and pulmonary infiltrates (fata...Continue Reading

Citations

Jun 12, 2002·Current Treatment Options in Oncology·E E Cohen, E E Vokes
Sep 5, 2003·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Kumiko KarasawaIsamu Takahashi
May 6, 2009·American Journal of Clinical Oncology·Joseph I ClarkBahman Emami
Apr 2, 2003·Expert Opinion on Pharmacotherapy·Angela M DaviesDavid R Gandara
Jan 2, 2003·Head & Neck·Luka MilasKian K Ang
Aug 3, 2007·Pediatric Blood & Cancer·Janet L FranklinUNKNOWN Children's Oncology Group
Jul 1, 2011·Experimental and Therapeutic Medicine·Satoshi TabuchiMasaki Kitajima
Mar 15, 2020·Esophagus : Official Journal of the Japan Esophageal Society·Terufumi KawamotoKeisuke Sasai
Sep 26, 2003·Pancreas·F ViretM Giovannini
Aug 5, 2003·The Oncologist·Giorgio V Scagliotti, Andrew T Turrisi
Jul 8, 2000·The Oncologist·D Schrijvers, J B Vermorken
May 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Parvesh KumarRobert S DiPaola
Jun 16, 2014·Breast Cancer Research and Treatment·Claudia OmariniStephen R D Johnston
Sep 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anne S TsaoBonnie S Glisson
May 21, 2003·American Journal of Therapeutics·Robert J BehrensWilliam L Dahut
Sep 7, 2000·International Journal of Radiation Oncology, Biology, Physics·J R BellonM M Austin Seymour
Jul 4, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M OkaS Kohno
Feb 25, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A C LockhartUNKNOWN American College of Surgeons Oncology Group
Mar 10, 2004·Hematology/oncology Clinics of North America·Yuhchyau Chen, Paul Okunieff

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.